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Advances in the immunosuppressive therapy of 
organ graft rejection achieved using cyclosporin 
A (CsA) and, more recently, FK506, have been 
ascribed to the selective and precise molecular 
• actions of these molecules in inhibiting signal 
transduction in alloactivated T cells. However, re-
cent evidence indicates that, following organ 
transplantation, the promotion of peripheral 
T cell tolerance to alloantigens using these and 
other drugs may be associated, just as signifi-
cantly, with a permissive effect of each drug on 
two-way (donor-recipient) leukocyte migration. 
This leads to a state of mixed allogeneic cell mic-
rochimerism in both the graft and the host. It has 
been proposed that this cellular chimerism is a 
natural consequence of organ transplantation 
under the umbrella of immunosuppressive drug 
therapy. Moreover, it is plausible that donor-
derived cells in the periphery of chimeras play an 
important role in achieving allotolerance, as many 
recent reports show that mature T cells can be 
tolerised after encountering antigen outside the 
thymus. The cell chimerism observed following 
organ transplantation in man may persist for 
many years after the time of grafting, even in 
patients who have discontinued all forms of im-
munosuppressive therapy. It seemed to us appro-
priate to conclude this book with a unifying 
hypothesis that places less emphasis on the pre-
vention of organ rejection by various immunosup-
pressive agents in terms of the molecular site of 
disruption of the alloactivated T cell response, 
and more on the permissive effect of these drugs 
on a two-way host-graft leukocyte migration and 
establishment of mixed microchimerism. 
Experimental and clinical 
observations 
It has been four decades since Billingham, Brent, 
and Medawar showed the causal relationship of 
haematopoietic chimerism to drug-free immuno-
logical tolerance.1.2 Almost immediately3 and 
during succeeding years,4-9 the adjuvant use of 
donor bone marrow or cells from the spleen or 
other lymphoid organs has been advocated to fa-
cilitate the transplantation of whole organs, while 
minimising the liability of immunosuppression. 
We have recently provided evidence that such 
strategies are an augmentation of a previously un-
recognised natural process of two-way migration 
of tissue leukocytes of bone marrow origin. 10-15 
Although multiline age , the most prominent of 
these migratory cells, once called 'passenger 
leukocytes,'16 were the dendritic cells delineated 
as a special white cell lineage in 1973 by Steinam 
and Cohn17- 20 and which are normally correlated 
with organ immunogenicity. 21-23 
In these recent studies, the dendritic and other 
donor cells were detected in the tissues of all func-
tioning human kidneyl4 and liver recipients15 ten 
to thirty years post-transplantation, and in recipi-
ents of other kinds of grafts who were studied 
after shorter follow-up periods. There was no im-
plication of drug specificity in these findings, be-
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cause the chimeric state had been induced under 
azathioprine-, cyclophosphamide-, cyclosporin A-
(CsA), and FKS06-based protocols with further 
immune modulation by steroids, poly- or mono-
clonal anti lymphoid globulins, splenectomy, and 
even thymectomy. A number of these patients 
had been off all immunosuppressive medications 
for years. When on or off maintenance therapy, 
essentially all of the patients tested with mixed 
lymphocyte reaction (MLR) or cell-mediated 
lymphocytotoxicity methods had some element of 
donor-specific non-reactivity. The variable ability 
of different organs to produce chimerism and 
consequently maintain for themselves such 
narrow nonreactivity, ultimately allowing drug in-
dependence in many of these cases, was explained 
hy their comparative content of the migratory 
leukocytes. This is thought to be greatest with the 
liver and smallest with the heart and kidney. 15 
The conclusion from these clinical studies was 
that cell migration and subsequent chimerism 
might be an integral requirement for graft accept-
ance, as well as the seminal step in tolerance in-
duction for whole organs. Little, however, was 
known of the events between the transplant oper-
ation and the observations made years later. In-
formation which helps to fill this gap has been 
provided by studies in rat5. 24 Although cell mi-
gration is a generic phenomenon after the trans-
plantati)n of all organs, the liver transplant model 
was selected for the animal experiments because 
the voluminous traffic to and from this organ is 
ideal for study of the participating cells. While 
underscoring the role of dendritic cells, the results 
demonstrated that both the acute leukocyte mi-
gration and the ensuing long-term chimerism were 
prohably multilineage. Donor T and B lympho-
cytes, as well as dendritic cells and macrophages 
from the transplanted liver localised promptly to 
the spleen, lymph nodes, and thymus of the re-
cipient. B lymphocytes homed to the B cell zones, 
while T cells migrated to those areas where re-
cipient T lymphocytes were normally concen-
trated. In essence, the traffic routes approximated 
those utilised by phenotypically identical recipient 
cells. 25 For the first three to five days post-
transplant, these patterns were not obviously dif-
ferent with the use or omission of systemic 
immunosuppressive therapy. After a further few 
days, however, the emigrant donor cells dis-
appeared in the untreated recipients. 
In contrast, the various donor cells in the rat 
liver graft recipients immunosuppressed with a 28-
day course of FKS06 persisted in the locations 
expected of phenotypically identical recipient 
lymphoid organs. In addition, a ubiquitous spread 
was evident after two to four weeks, with the 
arrival of the donor cells in the skin and heart -
in the same way as after bone marrow transplanta-
tion,12 and after allogeneic foetal liver transplan-
tation. 26 After this time, the process proceeded 
and was sustained without the need for intensive 
maintenance therapy, or in the absence of all 
further treatment. 
Accommodation of earlier experimental 
findings 
The results of earlier experimental animal work 
(the so-called 'parked' kidney experiments) have 
provided a counter argument to the view that 
cellular chimerism may be the cause rather than 
the result of sustained allograft transplantation. 
We will discuss these briefly. 
In the two stage kidney graft parking 
models,27.28 stage one consists of the induction of 
permanent organ acceptance in the rat using drug 
or irradiation treatment. Following replacement 
of passenger leukocytes by host migratory cells, 
the composite organ is retransplanted into naive 
recipients (second stage). It is rejected by naive 
animals of the donor but not the recipient strain. 
These results, however, can only be accomplished 
using immunologically 'easy' rat strain combi-
nations27 ,28 or with perfect major histocompati-
bility complex (MHC) matching in larger 
animals. 29 Even under these circumstances, the 
outcome tends to be variable. 
Although the parking model has provided a 
useful research tool, the results cannot be ex-
trapolated freely to a discussion of the cell mi-
gration concept. This is because neither the host 
immunocytes (including those that 'home' to the 
parked organ) nor the donor leukocytes (which 
are seeded ubiquitously in the recipient) remain 
the same. The non-responsiveness induced after 
cell migration involves both graft versus host 
(GYH) and host versus graft (HVG) reactions. 
The reciprocal, educational process of donor and 
recipient leukocytes and its perpetuation in either 
direction resembles the 'infectious' transplanta-
tion tolerance described by Waldmann and col-
leagues30 that can be passed on to naive 
lymphocytes and is self-sustaining in some circum-
stances. In successful cases, the graft mini im-
mune system is incorporated into the existing 
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immunological network of the recipient, compat-
ible with the hypothesis of Coutinho (see below). 
Incomplete assimilation on the HVG limb is 
monitored by evidence of rejection, which has 
been the sole measurable end point of all parking 
experiments. 
Assimilation on the GVH limb is also ordinarily 
silent. It can however be unmasked in transplanta-
tion experiments using the LEW to BN rat strain 
combination that is inherently prone to GVH dis-
ease (GVHD).31.32 The experiments we have con-
ducted consisted of simulating the natural cell 
migration that occurs after organ transplantation 
by the administration of bone marrow infusion. 
At the same time or later, the migratory passenger 
leukocyte load brought in with a contempor-
aneous or delayed liver or heart allograft was 
added. 24 In these rat experiments, liver transplan-
tation plus donor strain bone marrow did not 
cause G YHD when both engraftments were done 
simultaneously under immunosuppression. 
When, however, chimerism was induced with pre-
liminary bone marrow transplantation, followed 
by a 28-day course of FK506, then a drug free 
interval of 18 days, subsequent liver transplanta-
tion invariably caused lethal GVHD. 
The outcome with delayed hepatic transplanta-
tion resembled that of a parent to offspring Fl 
hybrid experiment in that the liver, including its 
virgin migratory cells, was seen as self by the 
altered host immune system. Not having gone 
through the process of modification, however, the 
hepatic passenger leukocytes reciprocated by re-
jecting the defenseless recipient. In contrast, het-
erotopic hearts transplanted under the same 
circumstances of prior bone marrow preparation 
were accepted, without causing clinical GVHD. 
presumably reflecting the smaller supply of car-
diac passenger leukocytes. 
The common effect of 
immunosuppressive drugs 
These experimental studies and the preceding 
clinical ones emphasise how a variety of potenti-
ally immunogenic and/or tolerogenic signals are 
delivered after whole organ transplantation to all 
of the lymphoid organs and then throughout the 
recipient by donor leukocytes. The consequences 
are drastically different in untreated compared 
with treated animals, but the ultimate therapeutic 
effect is obviously not defined by drug action 
alone. The testing of every genuinely potent im-
munosuppressant during the last 30 years has 
been followed by claims of tolerance induction in 
experimental animals, defined by the permanent 
acceptance of organ grafts after a course of im-
munosuppression without further treatment or 
with minimal maintenance therapy33-41 (Table 
17.1 ). 
The exact site of the drug action has not seemed 
critical, - whether this be at the level of antigen 
presentation (deoxyspergualin), gene transcrip-
tion (FK506 and CsA), interdiction of cytokine 
action (rapamycin), or prevention of clonal ex-
pansion by compounds that inhibit DNA synthesis 
(azathioprine or mizoribine). This generalisation 
Table 17.1 Tolerance induction by various 
immunosuppressive agents 
Agent (structure) Reference 
Inhibitor of monocyte-macrophage fimction 
Deoxyspergualin Engemann el al. 
(semisynthetic polyamine) E19~~Fgg 
Monoclonal antibodies against 'adhesion molecules' 
Anti-CD4 Shizuru et al. (1990)'4 
Anti-LFA-l Nakakura et al. 
(1993)35 
Anti-ICAM-l (in Isobe et al. (1992)3<> 
combination with anti-
LFA-l) 
Inhibitors of cytokine (IL-2) production 
CsA (cyclic peptide) White et al. (1980)37 
FK506 (carboxycyclic Ochiai et al. (1987)3H 
lactone) 
Inhibitors of cytokine (IL-2) action 
Rapamyein (earboxycyclic Kahan et al. (1991)'" 
lactone) 
Anti-lL-2R (p55 a-chain) 
monoclonal antibody 
Inhibitors of DNA synthesis 
Azathioprine (6-
mercaptopurine derivative) 
Cyclophosphamide 
Mycophenolate mofetil* 
(RS-61443) 
(morpholinoethyl ester of 
mycophenolic acid) 
Brequinar sodium 
(quinoline carboxylic acid 
derivative) 
Kirkman et al. 
E19~RF41g 
Mayumi and Good 
(1989)41 
Hao et al. (1992)42 
Cramer et al. (1992)43 
""New' immunosuppressive drugs such as mycophcnolatc 
mofetil (RS-61443) or SK&F 105685 may also induce immune 
suppressioll by modulatioll of adhesion molecule expressioll, 
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applies also to the biological compounds that in-
clude not only those that are T cell depleting, 
antilymphocyte globulins, but also non-T cell de-
pleting monoclonal antibodies, such as those di-
rected against the cell surface CD4 antigen or 
against intercellular adhesion molecules like inter-
cellular adhesion molecule-l (ICAM-l) and lym-
phocyte function associated antigen-l (LF A-I). 
Thus, variably non-specific immunosuppression 
can lead to donor-specific tolerance. 
We have postulated previously!3 that the 
commonality of the end result with all of these 
diverse agents is their permissive as opposed to 
their direct effect, allowing the cell chimerism and 
consequent bodywide engagement of donor and 
recipient cells. The chimerism in this hypothesis 
may be the cause of variable non-reactivity in-
volving the donor-recipient relation that mayor 
may not require lifetime immunosuppression for 
stability. How the non-reactivity occurs remains 
speculative, but it is clear that the alteration 
affects both the reactivity of the recipient immune 
apparatus toward the passenger leukocytes as well 
as the other way round. 
Peripheral T cell anergy 
It is not known how co-existing donor and re-
cipient immunocyte populations in mixed chim-
erism come to regard each other 'in a revised light' 
(functional silencing). On the basis of recent ex-
perimental observations in animal models and 
man, however, it has been proposed that a state 
of T cell anergy can arise in the absence of clonal 
deletion (the most efficient way of ensuring toler-
ance, as predicted by Burnet's clonal selection 
theory). Recent evidence indicates the existence 
of various (multiple) levels of peripheral T cell 
tolerance, characterised by modulation (down-
regulation) of the T cell receptor (TCR) and ac-
cessory molecules, such as CDS.44 We define 
anergy in this context as a lack of clonal deletion, 
with non-reactivity to MHC class IT antigens in ill 
vitro MLR. The mechanisms inducing this form 
of extrathymic (peripheral) tolerance are strong 
enough to overcome even such powerful reactions 
as those mounted against MHC class I molecules, 
which otherwise lead either to allograft rejection 
or lethal G VHD. 
Generation of a T cell-mediated immune re-
sponse, which leads to graft destruction under 
normal circumstances, requires effective antigen 
presentation and recognition in its initial phase, 
together with receipt of a second co-stimulatory 
signal and the response of T helper 1 (T HI) cells 
to the combined signal. 45 Both of these signals 
are normally delivered to T cells by professional 
antigen-presenting cells (A PC) , including (acti-
vated) B cells and above all, the dendritic cells 
that ultimately dominated the migration patterns 
in our experimental animal studies and in the 
human observations. The dendritic cell (and per-
haps other cells, in particular B cells) is critical 
because it can modify the expression of cell inter-
action, adhesion and MHC molecules, all of 
which determine how antigen signals are heeded 
by T cells (Figure 17.1). Unless activated, B cells 
appear unable to provide co-stimulatory signals 
and can induce transplantation tolerance. 46 Mol-
ecules that can promote adhesion and can deliver 
activation signals to T cells include LFA-l, CD2 
and CD28, the ligands of which are ICAM-1, 
LFA-3 and B7, respectively. 
Clues to possible mechanisms underlying a state 
of mixed cellular unresponsiveness come from 
studies of alloantigen-pretreated, graft-tolerant 
animals in which induction of T cell anergy has 
THE IMMUNOLOGIC INTERFACE 
Fig. 17.1 The molecular interface between the Til cell and an 
APC and hetween a cytotoxic T cell and an allogeneic target 
cell. Antigen (circle) is depicted in conjunction with cell surface 
MHC class T or II molecules. Second signal for Til cell activa-
tion may be provided by the CD2S-B7 receptor-ligand inter-
action (not shown). Interference with these molecular 
interactions or with signals resulting from them can lead to 
tolerance induction. 
---------------------------
been implicated. The intravenous route is the 
most effective for induction of tolerance due pre-
sumably, to the route of trafficking of antigen to 
the lymphoid tissue. Thus, in animals given a single 
allogeneic blood transfusion prior to organ trans-
plantation from the same donor strain, it appears 
that the primary but not the necessary second 
signal for full and sustained T cell activation is 
provided. Presentation of donor MHC class I or 
II antigens on gene-transfected fibroblasts (non-
professional APCs) before transplantation can 
also induce specific unresponsiveness. 
In the absence of co-stimulatory factor activity, 
there is disruption ofthe interleukin 2 (IL-2) cyto-
kine-cytokine receptor autocrine pathway. Direct 
interference with the IL-2 pathway using CsA or 
FK506 (both of which inhibit IL-2 gene transcrip-
SITES OF ACTION OF TOLERANCE -INDUCING AGENTS 
DSG 
AZATHIOPRINE CYCLOPHOSPHAMIDE RS61443 
BREQUINAR SODIUM 
CaA 
FK506 
Fig. 17.2 Sites of action of immunosuppressive drugs and 
monoclonal antibodies (McAbs) which have the capacity to 
induce tolerance to organ allografts in experimental animals. 
Common to all of the drugs shown is the ability to (ultimately) 
inhibit T cell proliferation. Monoclonal antibodies which can 
induce tolerance in animals include non-T cell depleting anti-
CD4 and anti-LFA-l + anti-ICAM-l antibodies. DSG = 
deoxyspergualin. APC = antigen-presenting cell, Til = T 
helper cell, IL·2R = interleukin 2 receptor. 
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tion) or monoclonal antibodies directed against 
IL-2 or the IL-2 receptor (IL-2R) is highly effec-
tive in inducing immune suppression and has pro-
found implications for the induction of peripheral 
tolerance (Figure 17.2). It appears that in animals 
made tolerant by infusion of allogeneic leuko-
cytes, there is normal IL-2 gene induction but low 
IL-2R gene induction. This may reflect abnormal 
translational control of IL-2 production (although 
no such regulation has previously been described 
for the IL-2 gene). Alternatively, it is possible 
that an (as yet unidentified) IL-2 or IL-2R antag-
onist may exist in a fashion analogous to the IL-1 
receptor antagonist. 47 ,48 It has been proposed 
(see, e.g., Jenkins49) that TCR occupancy leads 
to the production, through an active metabolic 
process, of negative regulators ('anergy proteins') 
that accumulate at later times and repress IL-2 
gene transcription, possibly by antagonising the 
effects of positive cytokine gene transcription fac-
tors. In support of this hypothesis, T cell specific 
negative regulation of transcription of cytokine 
(IL-4) has recently been described. Moreover, a 
T cell-specific protein which can down regulate 
IL-4 promoter activity has been identified. 5u 
There is also evidence of cellular protein binding 
to the negative regulatory elements of the IL-2R 
2-chain gene. 51 Within murine anergic T HI cell 
clones, this effect on cytokine gene expression 
may relate only to IL-2, as other cytokines such 
as IL-3 or y-interferon (IFN-y) may be secreted, 
albeit at suboptimal levels. 
Under cover of potent immunosuppressive 
drugs which inhibit IL-2 production (CsA or 
FK506) and in the continuous presence of (graft) 
alloantigens, it is likely that the chronically stimu-
lated T cell will continue to make negative regu-
lators, thus reinforcing the state of anergy (see 
Figure 17.3). Anergic T cells remain viable and 
can proliferate in response to exogenous IL-2. It 
is also possible that anergy can be induced in IL-2-
producing T cells that receive both TCR and co-
stimulatory signals, but are prevented from 
responding to IL-2 or dividing by for example 
rapamycin (which blocks IL-2R-induced cell cycle 
S phase entry) or inhibitors of DNA synthesis, 
such as mycophenolate mofetil (RS-61443) or bre-
quinar sodium, respectively (Figure 17.2). 
Antigen-specific anergy may ensue in a manner 
analogous to that observed in chronic microbial 
infection. 52 Significantly, Malkovsky and Med-
awar53 showed that IL-2 administration to mice 
reversed neonatal tolerance, consistent with the 
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Fig. 17.3 Model of dendritic cell (APC)-T", cell interaction, 
showing the production within the nucleus of positive (+) and 
of negative (-) rcgulators (anergy proteins) of IL-2 gene 
transcription. In this model, anergy relates only to the IL-2 
gene and other cytokincs (e.g. IFN-y) may be secreted. albeit at 
suhoptimal Icv<:ls. In the absence of persisl<:nt co-stimulatory 
signals (or under the umbrella of immunosuppressive drugs), 
cell division does not proceed and negative nuclear regulators 
accumulate, resulting in Tcell anergy. In addition to the action 
of immunosuppressive agents, chronic antigen stimulation is 
also envisaged as promoting anergy. In some instances, toler-
ance can be broken, e.g. by administration of exogenous [L-2. 
HVG = host versus graft response (allograft rejection), GVHD 
= graft versus host disease. 
view that a defect in signalling via a single cyto-
kine might underlie and maintain the tolerant 
state. More recently, Dallman et at54 reported that 
T cells infiltrating cardiac allografts of tolerant 
rats exhibited reduced cell surface expression of 
the IL-2Ra chain, and reduced IL-2Ra and fi-Oo~ 
mRNA expression. Although the IL-2 gene was 
induced, cells from the tolerant animals failed to 
make IL-2 in culture. Others have shown, using 
cell culture models of T cell clonal anergy, that 
IL-2 can reverse antigen-induced unresponsive-
ness in cloned T cells. 55 
There is clearly good evidence that peripheral 
T cell anergy can result after antigen presentation 
by APCs in the absence of the essential second 
signal. One of the principal candidates for the 
second signal is activation via the cen surface 
CD28 molecule (which requires primary signalling 
through the CD3-TCR or CD2 proteins) and 
which increases both the rate of transcription and 
mRNA stability of several cytokine genes, in-
cluding IL-2.56 Anti-CD28 monoclonal antibody 
or transfectants expressing B7, the ligand of 
CD28, provide the co-stimulatory function of 
APCs. Unlike CsA and FK506, which inhibit 
T cell activation via the TCR-CD3 pathway, and 
which fail to block activation via CD28, rap a-
mycin is effective in inhibiting anti-CD28-induced 
proliferation. 
Cytokines derived from T H cells may also be 
involved in the induction of APC unresponsive-
ness. Thus, recent work distinguishing T H cells 
as T HI and T H257 suggests a role for T H2 cells in 
suppression. By releasing IL-IO (cytokine syn-
thesis inhibitory factor), T H2 cells are believed to 
inhibit the function of APC and thereby indirectly 
the production of cytokines (e.g. IL-2), which are 
important in T HI cell responses. 58 Significantly, 
both FK506 and CsA have been shown to spare 
IL-lO mRNA expression by a murine THz cell 
clone (see Chapter 7). This may, at least in part, 
contribute to their immunosuppressive and toler-
ance-inducing activities in vivo. 
Tolerance in mature T cells can be induced by 
interference with accessory molecule expression 
using, for example, non-depleting anti-CD4 or 
anti-CD8 monoclonal antibodies which induce 
tolerance to skin and other grafts. Thus, in anti-
body-treated mouse Mls"/Mlsb combinations, 
T cells are unable to proliferate in response to 
appropriate stimulator cells in vitro. These find-
ings endorse the view that T cell immune recog-
nition requires the contribution of the TCR as 
well as adhesion receptors, which promote the 
attachment of T cells to APCs and transduce regu-
latory signals for T cell activation. The LFA-l 
and ICAM-l adhesion molecules form one such 
heterophilic receptor-ligand pair. LF A -1, a candi-
date for the co-stimulatory signal, is required for 
a range of leukocyte functions, including 
lymphokine production by T cells in response to 
APCs and killer T cell-mediated target cell lysis. 
Activation of antigen receptors on T cells allows 
LFA-l to bind its ligand with higher affinity. Also, 
the LFA-l:ICAM-1 interaction is required for op-
timising T cell function in vitro. Monoclonal anti-
bodies to these molecules are important potential 
agents for the prevention of graft rejection. The 
combination of anti-LFA-1 and anti-ICAM-1 
monoclonal antibodies has been reported to lead 
to specific tolerance in a mouse heterotopic car-
diac allograft model. 36 
Relation to other tolerance-inducing 
mechanisms 
Recent reviews have emphasised the inadequacy 
of intrathymic clonal deletion to explain adult ac-
quired transplantation tolerance and have focused 
on post-thymic mechanisms that include periph-
eral clonal deletion and anergy. The evidence for 
cell chimerism persisting in tissues of organ graft 
recipients as long as three decades after transplan-
tation, is especially supportive of the concepts ex-
pounded by Coutinho and colleagues59,60 and 
Cohen.61 They have defined tolerance as a high 
(not anergic) level of sustained lymphocyte 
activity in complex communicating networks. 
Suppressor cells and/or veto cells could be epi-
phenomena of this activity. According to these 
views, if 'self' is positively defined by activated 
'connected' lymphocytes, then alloreactive clones 
should be stimulated rather than suppressed if the 
recipient immune system is to consider the grafted 
tissues as self. On the other hand, if the immuno-
logical self of the donor is defined by its immune 
network, successful transfer of components of 
that network to graft recipients should assure 
donor-specific tolerance to the graft. An essential 
prerequisite for the transfer of these essential 
cellular components and for the establishment of 
cell chimerism would be an appropriate level of 
recipient systemic immune suppression, as can be 
achieved routinely using the variety of immuno-
suppressive agents considered above. It should 
now be possible, using drugs with known sites of 
molecular action, to pose specific questions about 
the relationship of drug-induced transplantation 
tolerance to the classical tolerance produced in-
itially by Billingham, Brent and Medawar.1,2 
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